ReviewMedical oncology (Northwood, London, England)1999
Interleukin-10: a cytokine used by tumors to escape immunosurveillance.
Review in Medical oncology (Northwood, London, England), 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Nifetepimine, a dihydropyrimidone, ensures CD4+ T cell survival in a tumor microenvironment by maneuvering sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA).The Journal of biological chemistry · 2012Trial
- Tumor-associated macrophages: potential therapeutic strategies and future prospects in radioresistance of cancer.Frontiers in immunology · 2026Review
- Review
- Natural killer cells in cancer immunotherapy.MedComm · 2024Review
- Article
- Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy.Journal of immunology research · 2020Review
- A Systematic Review Exploring the Anticancer Activity and Mechanisms of Glucomannan.Frontiers in pharmacology · 2019Review
- Synthetic analysis of associations between IL-10 polymorphisms and skin cancer risk.Oncotarget · 2018Article
- Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation.International journal of oncology · 2017Article
- Manipulation of regulatory T cells and antigen-specific cytotoxic T lymphocyte-based tumour immunotherapy.Immunology · 2015Review
- Role of Dendritic Cells in the Induction of Lymphocyte Tolerance.Frontiers in immunology · 2015Review
- Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms.British journal of cancer · 2014Article
- Mouse Model of Devil Facial Tumour Disease Establishes That an Effective Immune Response Can be Generated Against the Cancer Cells.Frontiers in immunology · 2014Article
- Article
- Article
- Expression of Leukocyte Inhibitory Immunoglobulin-like Transcript 3 Receptors by Ovarian Tumors in Laying Hen Model of Spontaneous Ovarian Cancer.Translational oncology · 2012Article
- Increased IL-10 mRNA expression in tumor-associated macrophage correlated with late stage of lung cancer.Journal of experimental & clinical cancer research : CR · 2011Article
- Dendritic cell control of tolerogenic responses.Immunological reviews · 2011Review
- Haplotype-dependent differential activation of the human IL-10 gene promoter in macrophages and trophoblasts: implications for placental IL-10 deficiency and pregnancy complications.American journal of reproductive immunology (New York, N.Y. : 1989) · 2010Article
- Skin cancer in asians: part 1: nonmelanoma skin cancer.The Journal of clinical and aesthetic dermatology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mechanisms whereby malignant cells can elude the recognition of the immune system, by what is termed 'immunological escape', have attracted major attention of tumor immunologists during the past decade. In this review, the role of the immunosuppressive cytokine interleukin-10 (IL-10) will be discussed as a strategy used by tumors to avoid recognition by cytotoxic T lymphocytes (CTL).
Indexed as
Identifiers
10456656What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.